- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03669354
Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care
Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care of Aged Medicare Beneficiaries With Chronic Low Back Pain
연구 개요
상태
정황
상세 설명
Research Design
This description applies to project specific aim 2.
Overview of Design and Methods: FFS Medicare beneficiaries will be surveyed and compared by cohort for differences in response. Subjects will be randomly sampled from each of the four cohorts (A, B, A2B & B2A) identified in SA1.
Survey Instrument and Question Formulation: A validated survey instrument will be used to collect subjective patient data. The survey will include questionnaires intended to evaluate 1) self-reported QOL, 2) satisfaction with care, and 3) beliefs regarding back pain and its treatment. For assessment of self-reported QOL a version of the SF12 (Ware '96) will be used and modified to account for time lapse between treatment for LBP and administration of the survey, and to elicit treatment-specific responses The SF -12 has been previously validated for measuring QOL among elderly patients, (Jakobsson '07) and patients using prescription drugs. (Naveiro-Rilo '14) For assessment of satisfaction with care a 0-10 numeric scale will be used. For assessment of beliefs a modified version of the validated LBP Treatment Beliefs Questionnaire will be used. (Dima '15). A pre- test of all the survey instruments will be conducted by distributing a prototype to a sample of 100 Medicare beneficiaries seen for LBP at the SCU Health Center in Whittier, CA. Responses to the survey pre-test will inform any need to edit the questionnaire for comprehensibility and ease of use, thus helping to ensure instrument face validity. For ease of comprehension by older subjects, the survey questions will be printed in large font and will be carefully worded to be brief, unambiguous, and free of bias.
Survey Methods: ResDAC will initiate contact with random samples of beneficiaries who meet criteria for inclusion in the cohorts identified in SA1. The Beneficiary Contact Service has reviewed the survey plan with the PIs and provided an official cost estimate for this service, which is routinely provided by the BCS with strict attention to patient protection. Initial contact will be in the form of a Beneficiary Notification Letter, signed by the CMS Privacy Officer. The letter will alert beneficiaries to the opportunity to voluntarily participate in a healthcare survey. Recipients will be informed that they may decline participation via enclosed reply forms, and will be given phone numbers to call CMS personnel for additional information. After three weeks, the Beneficiary Contact Service will supply the investigators with contact information for eligible beneficiaries (those who did not decline to participate). The survey will be commenced by mailing the printed survey, cover letter with informed consent form based on NCCIH guidelines, and a postage-paid return envelope with detailed information about the survey. Participants can contact study personnel if they have any questions. Follow up by phone after every two weeks or as needed will be used to increase the rate of response.
Outcomes Measurement and Statistical Analysis: Testing will be done for between-cohort differences in self-reported QOL, satisfaction with care, and beliefs about treatments for LBP. Survey responses between the four groups will be compared using Pearson chi-square tests and ANOVA. Demographic characteristics [e.g. sex as a biological variable, and age - because age-related cognitive decline can affect survey responses (Wolinsky '15)] will be controlled using linear regression for continuous survey items, proportional odds logistic regression for ordinal items and multinomial regression for categorical items. In the multivariable regression models equivalence between the four groups will be evaluated using likelihood ratio or Wald tests. Given the multiplicity of testing (e.g. multiple groups for multiple items), type I error inflation will be considered through used of Bonferonni corrections or approaches for false discovery rates. Parametric tests of numeric data can be used to yield unbiased answers when analyzing Likert scale responses. (Norman '10)
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
California
-
Whittier, California, 미국, 90604
- Southern California University of Health Sciences
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Subjects will include Medicare Fee for Service beneficiaries (male or female), aged 65-84 years, residing in the US, and enrolled under Medicare Parts A, B, and D who have experienced an episode of chronic low back pain (defined as lasting three months or longer).
Exclusion Criteria:
- Subjects with diagnosis of cancer will be excluded from the study population to avoid confounding of the reason for use of prescription opioids. Subjects over the age of 85 will also be excluded.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
Cohort SMT
Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
|
Cohort OAT
Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
|
Cohort SMTX
Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
|
Cohort OATX
Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Self-reported QOL - Physical Health
기간: Base line. The survey (outcome measure) will be administered at at day one.
|
|
Base line. The survey (outcome measure) will be administered at at day one.
|
Satisfaction With Care
기간: Base line.The survey (outcome measure) will be administered at day one.
|
|
Base line.The survey (outcome measure) will be administered at day one.
|
Beliefs Regarding Back Pain and Its Treatment
기간: Base line.The survey (outcome measure) will be administered at at day one.
|
|
Base line.The survey (outcome measure) will be administered at at day one.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Anupama Kizhakkeveettil, PhD, Southern California University of Health Sciences
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
하부 요통에 대한 임상 시험
-
FibroGenAstraZeneca; Astellas Pharma Inc종료됨기본 MDS(Very Low, Low 또는 Intermediate IPSS-R with미국, 호주, 벨기에, 독일, 이스라엘, 이탈리아, 대한민국, 러시아 연방, 스페인, 영국, 프랑스, 칠면조, 캐나다, 덴마크, 인도, 폴란드
-
Université Victor Segalen Bordeaux 2Nanox International Laboratory (Belgique)완전한
-
Eisai Inc.완전한LEC(Low Emetogenic Chemotherapy)를 받기 위해 확인된 악성 질환이 있는 환자 또는 LEC의 마지막 주기 동안 최소한 메스꺼움 및 구토를 경험한 환자미국